Targeting splicing in the treatment of human disease

40Citations
Citations of this article
149Readers
Mendeley users who have this article in their library.

Abstract

The tightly regulated process of precursor messenger RNA (pre-mRNA) alternative splicing (AS) is a key mechanism in the regulation of gene expression. Defects in this regulatory process affect cellular functions and are the cause of many human diseases. Recent advances in our understanding of splicing regulation have led to the development of new tools for manipulating splicing for therapeutic purposes. Several tools, including antisense oligonucleotides and trans-splicing, have been developed to target and alter splicing to correct misregulated gene expression or to modulate transcript isoform levels. At present, deregulated AS is recognized as an important area for therapeutic intervention. Here, we summarize the major hallmarks of the splicing process, the clinical implications that arise from alterations in this process, and the current tools that can be used to deliver, target, and correct deficiencies of this key pre-mRNA processing event.

Cite

CITATION STYLE

APA

Suñé-Pou, M., Prieto-Sánchez, S., Boyero-Corral, S., Moreno-Castro, C., Yousfi, Y. E., Suñé-Negre, J. M., … Suñé, C. (2017, March 1). Targeting splicing in the treatment of human disease. Genes. MDPI AG. https://doi.org/10.3390/genes8030087

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free